Invion Ltd Provides Quarterly Update and Appendix 4C
Key points
- Progressed Oesophageal Cancer Program with funding from Hanlim and KDDF
- Advanced Animal Health Collaboration with Protect Animal Health
- Expanded Skin Cancer Trial to include Basal Cell Carcinoma patients
- Secured ~$1.3m in Convertible Note Offering
Full summary
Invion Limited (ASX: IVX) provided a quarterly update and Appendix 4C for the period ended 31 March 2026. The company held cash reserves of $395K at the end of the quarter, with key cash outflows for research and development ($405K) and administration/corporate costs ($430K). Invion continued to focus on advancing its Photosoft platform technology, including progressing preclinical work on its Oesophageal Cancer Program, which received ~$200K in funding from Hanlim Pharm Co., Ltd and the Korea Drug Development Fund. The company also advanced its Animal Health Collaboration with Protect Animal Health, which is progressing in vitro and in vivo studies using Photosoft. Additionally, Invion expanded its Skin Cancer Trial to include Basal Cell Carcinoma patients following encouraging preliminary results. The company also secured ~$1.3m in commitments from a convertible note offering, with the first tranche of $578K received in the quarter.
Outlook
The company expects to continue advancing its Photosoft platform technology across multiple programs, including the Oesophageal Cancer Program, Animal Health Collaboration, and Skin Cancer Trial. The successful convertible note offering will provide funding to support these ongoing initiatives.
Summary generated by a large language model. Please interpret with care.